Peptide-based radiopharmaceuticals for targeted tumor therapy

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Chemistry

Background:

• Peptide receptor radionuclide therapy (PRRT) utilizes radiolabeled peptides to target tumors, demonstrating positive outcomes in clinical trials for various cancers.
• Established radiopharmaceuticals like (90)Y-DOTA-TOC and (177)Lu-DOTA-TATE have shown symptomatic improvements and survival benefits.
• Beyond somatostatin analogs, peptides targeting receptors such as integrin αvβ3, GRPR, MC1-R, CCK, and GLP-1R are being developed.

Purpose of the Study:

• To review the current advancements in peptide-based radiopharmaceuticals for tumor-targeted PRRT.
• To summarize radiopharmaceuticals currently under clinical investigation.
• To highlight strategies for improving PRRT efficacy and safety.

Main Methods:

• Review of pre-clinical and clinical data on PRRT.
• Analysis of radiolabeled peptides targeting various tumor receptors.
• Examination of optimization strategies including amino acid modification, radionuclide selection, protective agents, and combination therapies.

Main Results:

• PRRT has demonstrated significant potential in improving tumor response, overall survival, and quality of life.
• Various radiolabeled peptides targeting specific receptors are under development and investigation.
• Strategies like optimizing peptide design, radionuclide choice, and combination treatments are being explored to enhance therapeutic outcomes.

Conclusions:

• PRRT is a promising therapeutic modality for various tumors.
• Continued research into novel radiopharmaceuticals and treatment strategies is crucial for maximizing PRRT's potential.
• Optimization and combination approaches are key to improving PRRT's effectiveness and patient safety.